Patents by Inventor Frederic GEISSMANN

Frederic GEISSMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase mutation-associated neurodegenerative disorders
    Patent number: 11957668
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: April 16, 2024
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Frederic Geissmann, Elvira Mass, Rocio Vicario
  • KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERS
    Publication number: 20230277512
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-1R inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 7, 2023
    Inventors: Frederic GEISSMANN, Elvira MASS, Rocio VICARIO
  • METHODS AND COMPOSITIONS FOR MODULATING LIPID STORAGE IN ADIPOSE TISSUE
    Publication number: 20230174633
    Abstract: The present technology provides compositions and methods for the treatment of diseases associated with abnormal lipid accumulation. In some embodiments, the present technology also provides methods of treating lipodystrophy, and disorders characterized by abnormal lipid accumulation and/or lipid storage in adipose tissue.
    Type: Application
    Filed: March 29, 2021
    Publication date: June 8, 2023
    Inventors: Frederic GEISSMANN, Nehemiah COX
  • Kinase mutation-associated neurodegenerative disorders
    Patent number: 11337965
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: May 24, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Frederic Geissmann, Elvira Mass, Rocio Vicario
  • KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERS
    Publication number: 20210315868
    Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.
    Type: Application
    Filed: August 24, 2018
    Publication date: October 14, 2021
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Frederic GEISSMANN, Elvira MASS, Rocio VICARIO
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF OSTEOPETROSIS
    Publication number: 20210205360
    Abstract: Disclosed herein are methods and compositions for treating, preventing, or ameliorating osteopetrosis. In some embodiments, the present technology relates to administering a composition comprising a therapeutically effective amount of engineered monocytic cells or wild-type monocytic cells from a healthy donor to a subject suffering from or at risk for osteopetrosis.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 8, 2021
    Inventors: Frederic GEISSMANN, James T. MULLER